Martin Weltman
Professor
Medicine
University of Sydney
Australia
Biography
Dr.MARTIN WELTMAN is an Associate Professor of Medicine, Nepean Clinical School
Research Interest
Associate Professor Weltman has several areas of research interest including -Non-alcoholic fatty liver disease (NAFLD)(natural history, prognostic indicators, pathogenetic mechanisms and therapies) -Alcoholic hepatitis -Clinical trials and therapy for chronic hepatitis C and B infection -Genomics for HCV -Therapies for inflammatory bowel disease and natural history of inflammatory bowel disease -Interventions for Barrett's oesophagus -Epidemiology and natural hisrtory of functional dyspepsia and irritable bowel syndrome -Autoimmune liver disease and primary biliary cholangitis -Novel Drug Trials: Hepatitis B and C, Crohn's disease and Ulcerative colitis, Primary Biliary Cirrhosis, Liver cancer, constipation, IBS, Non-alcoholic fatty liver disease
Publications
-
Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800.
-
Midgard, H., Hajarizadeh, B., Cunningham, E., Conway, B., Backmund, M., Bruggmann, P., Bruneau, J., Bourgeois, S., Dunlop, A., Weltman, M., et al (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 47, 230-238.
-
Cunningham, E., Hajarizadeh, B., Dalgard, O., Amin, J., Hellard, M., Foster, G., Bruggmann, P., Conway, B., Backmund, M., Weltman, M., et al (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 17(1), 1-12.
